# Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

> **NCT00441727** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2426 (actual)

## Conditions studied

- Gastric Ulcer
- Duodenal Ulcer

## Interventions

- **DRUG:** Esomeprazole 40 mg
- **DRUG:** Esomeprazole 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00441727
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 2426 (ACTUAL)
- **Last updated:** 2012-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441727, "Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00441727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*